Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma
H. S. Campos, I. Teixeira, M. B. G. Oliveira, D. G. Xisto, L. M. Lima, E. J. Barreiro, N. R. D. Rodrigues, T. Mauad, W. A. Zin, P. R. M. Rocco (Rio de Janeiro, São Paulo, Brazil)
Source: Annual Congress 2004 - Exploring new basic aspects of treatment of asthma
Session: Exploring new basic aspects of treatment of asthma
Session type: Thematic Poster Session
Number: 866
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. S. Campos, I. Teixeira, M. B. G. Oliveira, D. G. Xisto, L. M. Lima, E. J. Barreiro, N. R. D. Rodrigues, T. Mauad, W. A. Zin, P. R. M. Rocco (Rio de Janeiro, São Paulo, Brazil). Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma. Eur Respir J 2004; 24: Suppl. 48, 866
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Effect of a thrombin inhibitor on murine bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Terapeutic potential of different phosphodiesterase inhibitors in a model of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004
Effects of phosphodiesterase 3/4 inhibition on matrixmetalloproteinases 2 and 9 in chronic experimental pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Source: Eur Respir J 2003; 22: 20-27 Year: 2003
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017
Effects of combination treatments with the PPAR β/δ agonist GW0742 and the phosphodiesterase type V inhibitor, sildenafil on markers of pulmonary hypertension in hypoxic rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001